Dataset Information

Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma

ABSTRACT:

Background

Lung adenocarcinoma (LUAD) is the most frequently diagnosed histological subtype of lung cancer. Our purpose was to explore molecular subtypes and core genes for LUAD using multi-omics analysis.

Methods

Methylation, transcriptome, copy number variation (CNV), mutations and clinical feature information concerning LUAD were retrieved from The Cancer Genome Atlas Database (TCGA). Molecular subtypes were conducted via the “iClusterPlus” package in R, followed by Kaplan-Meier survival analysis. Correlation between iCluster subtypes and immune cells was analyzed. Core genes were screened out by integration of methylation, CNV and gene expression, which were externally validated by independent datasets.

Results

Two iCluster subtypes were conducted for LUAD. Patients in imprinting centre 1 (iC1) subtype had a poorer prognosis than those in iC2 subtype. Furthermore, iC2 subtype had a higher level of B cell infiltration than iC1 subtype. Two core genes including CNTN4 and RFTN1 were screened out, both of which had higher expression levels in iC2 subtype than iC1 subtype. There were distinct differences in CNV and methylation of them between two subtypes. After validation, low expression of CNTN4 and RFTN1 predicted poorer clinical outcomes for LUAD patients.

Conclusion

Our findings comprehensively analyzed genomics, epigenomics, and transcriptomics of LUAD, offering novel underlying molecular mechanisms for LUAD. Two multi-omics-based core genes (CNTN4 and RFTN1) could become potential therapeutic targets for LUAD.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12885-021-07888-4.

SUBMITTER: Zhao Y

PROVIDER: S-EPMC7942004 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundMultiomics data analysis based on high-throughput sequencing technology has become a hotspot in tumor investigation. The present study aimed to explore prognostic biomarkers via investigating DNA copy number variation (CNV) and methylation variation (MET) data in prostate cancer.MethodsWe obtained the messenger RNA (mRNA) expression, CNV, and methylated data of prostate adenocarcinoma (PRAD) samples via The Cancer Genome Atlas (TCGA)-PRAD cohort. We calculated and assessed the associations between CNV and RNA sequencing (RNA-seq), and between MET and RNA-seq via Pearson correlation coefficients. We then used the "iCluster" package to perform multigroup cluster analysis with CNVcor gene CNV data, METcor gene methylation data, and CNVcor and METcor gene mRNA data. The univariate Cox analysis was used to screen significant hub genes, and multivariate Cox analysis was used to construct risk a model. The nomogram was constructed based on "rms" package, and the immune infiltrating patterns were compared between high- and low-risk groups.ResultsA total of 477 PRAD samples with complete CNV, methylation, mRNA, and matched clinical information were included in our study. A list of 10,073 CNVcor genes and 9841 METcor genes were confirmed with a significance level of P<0.01. We found that CNVcor is more likely to appear on chromosome (chr)8, chr17, and chr10, while METcor is more likely to appear on chr1, chr19, and chr17. Based on the core genes, we finally classified the samples into 4 subtypes, incorporating iC1 (iCluster) (92 samples), iC2 (79 samples), iC3 (165 samples), and iC4 (141 samples). Furthermore, we constructed the prognostic model for PRAD based on the 5 genes (IER3, AOX1, PRKCDBP, UBD, and FBLN5). Nomograms incorporating risk score and other clinical variables were further constructed, and these nomograms exhibited superior predictive ability. We further compared the differential immune infiltrating patterns in 2 risk groups and found significantly low levels of infiltrating cluster of differentiation (CD)8+ T cells in high-risk samples.ConclusionsOur study integrated the multi-omics data to elucidate the molecular features of PRAD and pivotal genes for predicting prognosis.

Project description:IntroductionThe purpose of the study is to genomically characterize the biology and related therapeutic opportunities of prognostically important predominant histologic subtypes in lung adenocarcinoma (LUAD).MethodsWe identified 604 patients with stage I to III LUAD who underwent complete resection and targeted next-generation sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets platform. Tumors were classified according to predominant histologic subtype and grouped by architectural grade (lepidic [LEP], acinar or papillary [ACI/PAP], and micropapillary or solid [MIP/SOL]). Associations among clinicopathologic factors, genomic features, mutational signatures, and recurrence were evaluated within subtypes and, when appropriate, quantified using competing-risks regression, with adjustment for pathologic stage and extent of resection.ResultsMIP/SOL tumors had higher tumor mutational burden (p < 0.001), fraction of genome altered (p = 0.001), copy number amplifications (p = 0.021), rate of whole-genome doubling (p = 0.008), and number of oncogenic pathways altered ( p < 0.001) as compared with LEP and ACI/PAP tumors. Across all tumors, mutational signatures attributed to APOBEC activity were associated with the highest risk of postresection recurrence: SBS2 (p = 0.021) and SBS13 (p = 0.005). Three oncogenic pathways (p53, Wnt, Myc) were altered with statistical significance in MIP/SOL tumors. Compared with LEP and ACI/PAP tumors, MIP/SOL tumors had a higher frequency of targetable BRAF-V600E mutations (p = 0.046). Among ACI/PAP tumors, alterations in the cell cycle (p < 0.001) and PI3K (p = 0.002) pathways were associated with recurrence; among MIP/SOL tumors, only PI3K alterations were associated with recurrence (p = 0.049).ConclusionsThese results provide the first in-depth assessment of tumor genomic profiling of predominant LUAD histologic subtypes, their associations with recurrence, and their correlation with targetable driver alterations in patients with surgically resected LUAD.

Project description:ObjectivesLung adenocarcinoma (LUAD) is recognized as one of the most prevalent and deadliest malignancies around the globe. The molecular mechanisms behind LUAD have not been fully elucidated. This study was launched to explore LUAD-associated hub genes and their enriched pathways using bioinformatics methods.MethodsInformation on GSE10072 was retrieved from the Gene Expression Omnibus (GEO) database and analyzed via the Limma package-based GEO2R tool to obtain the top 100 differentially expressed genes (DEGs) in LUAD. The protein-protein interaction (PPI) network of the DEGs was drawn using the STRING website and was shifted into Cytoscape to screen the top 6 hub genes via the CytoHubba application. Furthermore, the expression analysis and validation of hub genes in LUAD samples and cell lines were done using UALCAN, OncoDB, and GENT2 databases. Moreover, OncoDB was also used for analyzing hub gene DNA methylation levels. In addition, cBioPortal, GSEA tool, Kaplan-Meier (KM) plotter, Enrichr, CancerSEA, and DGIdb were performed to explore some other important aspects of hub genes in LUAD.ResultsWe identified Interleukin 6 (IL6), Collagen, type I, alpha 1 (COL1A1), TIMP metallopeptidase inhibitor 1 (TIMP1), CD34 molecule (CD34), Decorin (DCN), and Secreted Phosphoprotein 1 (SPP1) genes as the hub genes in LUAD, out of which IL6, CD34, and DCN were significantly down-regulated while COL1A1, TIMP1, and SPP1 were significantly up-regulated in LUAD cell lines and samples of diverse clinical variables. In this study, we also documented some important correlations between hub genes and other parameters such as DNA methylation, genetic alterations, Overall Survival (OS), and 14 important states at the single cell level. Lastly, we also identified hub genes associated with the ceRNA network and 11 important chemotherapeutic drugs.ConclusionWe identified 6 hub genes involved in the development and progression of LUAD. These hub genes can also be helpful in the accurate detection of LUAD and provide novel ideas for treatment.